Melanoma

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

The skin cancer diagnostics company said it delivered 7 percent more DecisionDx-Melanoma test results in Q3 2020 than in the previous year's third quarter.

The tests are covered when the patient has a personal history of melanoma and the test has demonstrated clinical and analytical validity.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

The general LCD is covered for patients with a personal history of melanoma undergoing workups or being evaluated for treatment without metastatic disease.

The investment bank said that the company's noninvasive genomic test for melanoma detection could capture a large market currently served by invasive biopsies.

The firm said its genetic tests for breast, prostate, and colorectal cancers and melanoma assess a patient's personal cancer risks and guide personalized prevention.

The skin cancer diagnostics company said it delivered 19 percent fewer DecisionDx-Melanoma test results in Q2 2020 than in the previous year's second quarter.

The skin cancer diagnostics company said it delivered 42 percent more DecisionDx-Melanoma test results in Q1 2020 than in the previous year's first quarter.

The La Jolla, California-based developer of genomic melanoma tests posted nearly $1.6 million in revenues in Q4, up from $600,000 in Q4 2018.